Danish Medicines Agency reimburses two new drugs
This article was originally published in Scrip
Executive Summary
The Danish Medicines Agencyhas approved two drugs for general reimbursement in December so far:Astellas' Protopic (topical tacrolimus) for the treatment of atopic dermatitis and psoriasis, andNovartis's Elidel (pimecrolimus), for the treatment of inflammatory diseases including atopic dermatitis, irritant contact dermatitis, allergic contact dermatitis and psoriasis. Reimbursement decisions are based on Section 144 of the Danish Health Act. The Agency has now reimbursed 21 medicines and declined to reimburse five this year.